TGEN - Targeted Genetics Corporation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TGEN - Targeted Genetics Corporation

TGEN 6.380

+2.7%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Boyce Burge who wrote (3)	7/6/1997 3:30:00 PM
From: john b	of 557

From the Seattle Times business section 7/6/97. TGEN remains a "buy" at the Genesis Merchant Group where analyst Wole Fayemi sees a target price of $15 a share. The Seattle biotech "is significantly undervalued compared to its peers in the gene-therapy group," Fayemi wrote. Products to treat certain cancers and cystic fibrosis continue to show progress, "The company has a number of other products in the clinic and continues to expand its patent portfolio,"Fayemi wrote,"increasing the likelihood of at least one corporate partnership by year end." (report issued 6/19. So take this as interesting or just more of the same. JB

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next